BlossomHill Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 15.21 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 483.45M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.
Details
| Name | BlossomHill Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 69 |
| Founded | 2020 |
| Ipo Date | 2026-08-07 |
| Ceo | Jingrong Jean Cui |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 16.00 |
| Isin | US0951301003 |
| Cusip | 095130100 |
| Cik | 1839970 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Jingrong Jean Cui Ph.D. | Scientific Founder, President, Chief Executive Officer and Director |
| Dr. Yishan Li M.B.A., Ph.D. | Co-Founder and Executive Chairman |
| Jason A. Keyes M.B.A. | Chief Financial Officer and Executive Vice President |
| Dr. Geoff Oxnard M.D. | Chief Medical Officer and Executive Vice President |
| Dr. Vincent Liptak J.D., M.B.A., Ph.D. | General Counsel and Executive Vice President |
| Dr. Zachary F. Zimmerman M.D., Ph.D. | Senior Vice President of Clinical Development |
| Dr. Eugene Y. Rui Ph.D. | Senior Vice President of Chemistry |
| Dr. Z. Jesse Shao Ph.D., R.Ph. | Senior Vice President of CMC |
| Dr. Ashley Preston Ph.D. | Senior Vice President and Head of Regulatory Affairs and Quality Assurance |
| Dr. Antonio Garrido-Montalban Ph.D. | Senior Vice President of Drug Substance |
Contact
| Address | 10255 Science Center Drive, Suite 200, San Diego, California 92121, United States |
| Phone | (858) 732-3880 |
| Website | https://bhtherapeutics.com |